Related Experiment Video

Updated: Aug 29, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Molecular analysis of therapy resistance in gastric cancer

Hermann Lage1

  • 1Charité Campus Mitte, Institute of Pathology, Berlin, Germany. hermann.lage@charite.de

Digestive Diseases (Basel, Switzerland)
|January 31, 2004
PubMed

Insights

Therapy resistance in gastric cancer is a complex issue. This study identifies new resistance factors, like glypican-3 (GPC3), and examines known ones, such as MDR1/P-glycoprotein, to improve treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Therapy resistance is a major cause of treatment failure and mortality in gastric carcinoma.
  • Clinical resistance to chemotherapy in gastric cancer is multifactorial and heterogeneous, with no single predictive factor identified.
  • Understanding resistance mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate novel factors contributing to therapy resistance in gastric carcinoma.
  • To analyze the role of both known and potential new resistance factors in gastric cancer.
  • To utilize established in vitro models to explore the complexities of drug and thermosensitivity.

Main Methods:

  • Establishment of a panel of drug-sensitive, multidrug-resistant, and thermoresistant human gastric carcinoma cell lines (EPG85-257).
  • Comprehensive analysis using morphological, biochemical, cellular, and molecular biological techniques.
  • Functional investigations to evaluate identified cellular alterations and resistance factors.

Main Results:

  • Identification of potential new therapy resistance-associated factors, including glypican-3 (GPC3).
  • Evaluation of the impact of established drug resistance factors like MDR1/P-glycoprotein.
  • Characterization of cellular alterations associated with multidrug and thermoresistance.

Conclusions:

  • The study provides insights into novel factors involved in gastric carcinoma therapy resistance.
  • Understanding these factors, including GPC3 and MDR1/P-glycoprotein, can aid in predicting clinical outcomes.
  • This research contributes to developing strategies to overcome therapeutic failures in gastric cancer.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...